Cost-utility and cost-effectiveness analysis of a clinical medication review focused on personal goals in older persons with polypharmacy compared to usual care: Economic evaluation of the DREAMeR study.
Sanne VerdoornJeroen van de PolAnke M HövelsHenk-Frans KwintJeanet W BlomJacobijn GusseklooMarcel L BouvyPublished in: British journal of clinical pharmacology (2020)
The benefits of a patient-centred CMR were inconsistent with no benefits on HR-QoL measured with EQ-5D-5 L and small benefits on HR-QoL measured with EQ-VAS and health-related complaints with impact on patients' daily lives. Additionally, a CMR could potentially be cost saving from a societal perspective.